Question | Answer |
DEPRESSION IS WHAT KIND OF DISORDER | A MOOD/AFFECTIVE |
RELIEF OF SYMPTOMS OF DEPRESSION WITH ANTI-DEPRESSANT THERAPY CAN TAKE HOW LONG | 1-3 WEEKS |
WHEN CAN YOU EXPECT THE FULL BENEFITS OF ANTI-DEPRESSANT THERAPY TO TAKE PLACE | 2-3 MONTHS |
WHAT ARE THE FOUR MAIN GROUPS OF ANTI-DEPRESSANT MEDICATIONS | TCA'S/TRICYCLIC ANTI-DEPRESSANTS
SSRI'S/SELECTIVE SEROTONIN REUPTAKE INHIBITORS
MOAI'S/MONOAMINE OXIDASE INHIBITORS
ATYPICAL ANTIDEPRESSANTS |
WHAT MEDICATIONS ARE UNDER THE CLASSIFICATION OF TCA'S | AMITRIPTYLINE/ELAVIL
IMIPRAMINE/TOFRANIL
DOXEPIN/SINEQUAN
NORTRIPTYLINE/AVENTYL
TRIMIPRAMINE/SURMONTIL |
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF TCA'S | BLOCK REUPTAAKE OF NOREPINEPHRINE AND SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF THESE NEUROTRANSMITTERS |
WHAT ARE THE THERAPEUTIC EFFECTS OF TCA'S | DEPRESSION
DEPRESSIVE EPISODES OF BIPOLAR DISORDER
CHRONIC PAIN
ENURESIS |
WHAT ARE THE SIDE EFFECTS OF USING TCA'S | ORTHOSTATIC HYPOTENSION
ANTICHOLINERGIC EFFECTS
SEDATION
TOXICITY
DECREASED SEIZURE THRESHOLD
EXCESSIVE SWEATING |
WHAT ARE THE ANTICHOLINERGIC EFFECTS OF TCA'S | DRY MOUTH
BLURRED VISION
PHOTOPHOBIA
URINARY HESITANCY OR RETENTION
CONSTIPATION
TACHYCARDIA |
WHAT KIND OF TOXICITY RESULTS FROM USING TCA'S | CHOLINERGIC BLOCKADE AND CARDIAC TOXICITY EVIDENCED BY
DYSRHYTHMIAS
MENTAL CONFUSION
AGITATION
FOLLOWED BY
SEIZURES
COMA
POSSIBLE DEATH |
TCA'S ARE A PREGNANCY CATEGORY RISK? | C |
TCA'S ARE CONTRAINDICATED IN CLIENTS THAT ? | HAVE SEIZURE DISORDERS |
TCA'S ARE USED CAUTIOUSLY IN CLIENTS WITH | CORONARY ARTERY DISEASE
DIABETES
LIVER DISORDER
KIDNEY DISORDER
RESPIRATORY DISORDER
URINARY RETENTION AND OBSTRUCTION
ANGLE-CLOSURE GLAUCOMA
BENIGN PROSTATIC HYPERTROPHY
HYPERTHYROIDISM |
INTERACTIONS WITH TCA'S INCLUDE | MAOI'S AND ST JOHNS WORT = SEROTONIN SYNDROME
ANTIHISTAMINES = ADDITIVE ANTICHOLINERGIC EFFECTS
TCA'S DECREASE EPHEDRINE, AMPHETAMINE EFFECTS
ALCOHOL, ANTIHISTAMINES, BENZO'S, OPIOIDS = ADDED CNS DEPRESSANT
INCREASED EFFECTS OF EPINEPHRINE, DOPAMINE |
MEDICATIONS CLASSIFIED AS SSRI'S ARE | FLUOXETINE/PROZAC
CITALOPRAM/CELEXA
ESCITALOPRAM/LEXAPRO
PAROXETINE/PAXIL
SERTRALINE/ZOLOFT |
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF SSRI'S | SELECTIVELY BLOCK REUPTAKE OF THE MONOAMINE NEUROTRANSMITTER SEROTONIN IN THE SYNAPTIC SPACE THEREBY INTENSIFYING THE EFFECTS OF SEROTONIN |
THERAPEUTIC USES OF SSRI'S ARE | MAJOR DEPRESSION
OCD
BULIMIA NERVOSA
PMDD
PANIC DISORDER
PTSD |
SIDE EFFECTS OF SSRI'S ARE | SEXUAL DYSFUNCTION
CNS STIMULATION
WEIGHT LOSS (EARLY IN THERAPY)
WEIGHT GAIN (IN LATER THERAPY)
SEROTONIN SYNDROME
WITHDRAWAL SYMPTOMS
HYPONATREMIA
RASH
SLEEPINESS
FAINTNESS
LIGHTHEADEDNESS
GI BLEEDING
BRUXISM |
SEROTONIN SYNDROME MAY BEGIN WHEN | 2-72 HOURS AFTER STARTING THERAPY AND MAY BE LETHAL |
SIDE EFFECTS ASSOCIATED WITH SEROTONIN SYNDROME | MENTAL CONFUSION
DIFFICULTY CONCENTRATING
FEVER
AGITATION
ANXIETY
HALLUCINATIONS
INCOORDINATION
HYPERREFLEXIA
DIAPHORESIS
TREMORS |
WITHDRAWAL SYMPTOMS ASSOCIATED WITH SSRI'S
ARE | HEADACHE
NAUSEA
VISUAL DISTURBANCES
ANXIETY
DIZZINESS
TREMORS |
FLUOXETINE IS A PREGNANCY RISK CATEGORY | C |
FLUOXETINE AND PAROXETINE MAY INCREASE THE RISKS OF WHAT | BIRTH DEFECTS |
SSRI'S ARE CONTRAINDICATED IN CLIENTS TAKING | MAOI'S AND TCA'S |
SSRI'S ARE USED CAUTIOUSLY IN CLIENTS WITH | LIVER DYSFUNCTION
RENAL DYSFUNCTION
CARDIAC DISEASE
SEIZURE DISORDERS
DIABETES
ULCERS
HISTORY OF GI BLEEDING
TAKING NSAIDS
TAKING ANTI-COAGULANTS |
MAOI'S AND ST JOHNS WORT INCREASE THE RISK OF | SEROTONIN SYNDROME |
FLUOXETINE CAN DISPLACE WARFARIN/COUMADIN FROM BOUND PROTEIN AND RESULT IN WHAT | INCREASED WARFARIN LEVELS |
FLUOXETINE CAN INCREASE THE LEVELS OF TCA'S AND WHAT | LITHIUM |
FLUOXETINE SUPPRESSES PLATELET AGGREGATION AND THUS INCREASES THE RISK OF BLEEDING WHEN USED WITH WHAT | NSAID'S AND ANTI-COAGULANTS |
MEDICATIONS IN THE MAOI CLASS ARE | PHENELZINE/NARDIL
ISOCARBOXAZID/MARPLAN
TRANYLCYPROMINE/PARNATE
SELEGILINE/EMSAM-TRANSDERMAL MAOI |
THE EXPECTED PHARMACOLOGICAL ACTION OF MAOI'S IS | BLOCK THE MAO-A IN THE BRAIN THEREBY INCREASING THE AMOUNT OF NOREPINEPHRINE, DOPAMINE, SEROTONIN AVAILABLE FOR TRANSMISSION OF IMPULSES THIS INTENSIFIES THE RESPONSE AND RELIEVES DEPRESSION |
THERAPEUTIC USES OF MAOI'S ARE | ATYPICAL DEPRESSION
BULIMIA NERVOSA
OCD |
SIDE EFFECTS OF MAOI'S INCLUDE | CNS STIMULATION
ORTHOSTATIC HYPOTENSION
HYPERTENSIVE CRISIS
LOCAL RASH WITH TRANSDERMAL USE |
WHAT ARE THE SPECIFIC SIDE EFFECTS ASSOCIATED WITH THE CNS STIMULATION | ANXIETY
AGITATION
MANIA
HYPOMANIA |
WHAT CAUSES THE HYPERTENSIVE CRISIS ASSOCIATED WITH USE OF MAOI'S | TYRAMINE CONTAINING FOODS |
WHAT ARE THE SIDE EFFECTS OF HYPERTENSIVE CRISIS ASSOCIATED WITH THE USE OF TYRAMINES AND MAOI'S | HEADACHE
NAUSEA
INCREASED HEART RATE
INCREASED BLOOD PRESSURE |
MAOI'S ARE PREGNANCY RISK CATEGORY | C |
MAOI'S ARE CONTRAINDICATED IN WHAT TYPE OF CLIENTS | TAKING SSRI'S
THOSE WITH PHEOCHROMOCYTOMA
CARDIOVASCULAR DISEASE
CEREBRAL VASCULAR DISEASE
SEVERE RENAL INSUFFICENCY |
MAOI'S ARE USED CAUTIOUSLY IN CLIENTS WITH | DIABETES
SEIZURE DISORDERS
TAKING TCA'S |
TRANSDERMAL SELEGILINE/EMSAM IS CONTRAINDICATED IN CLIENTS TAKING | CARBAMAZEPINE/TEGRETOL
OXCARBAZEPINE/TRILEPTAL
WHICH MAY INCREASE THE BLOOD LEVELS OF THE MAOI |
INTERACTIONS WITH MAOI'S | INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS
TCA'S
SSRI'S
MEPERIDINE/DEMEROL
TYRAMINE RICH FOODS
VASOPRESSORS |
INDIRECT ACTING SYMPATHOMIMETIC MEDICATIONS PROMOTE THE RELEASE OF NOREPINEPHRINE AND CAN LEAD TO WHAT | HYPERTENSIVE CRISIS |
USE OF TCA'S AND MAOI'S CAN LEAD TO WHAT | HYPERTENSIVE CRISIS |
USE OF SSRI'S AND MAOI'S CAN LEAD TO WHAT | SEROTONIN SYNDROME |
ANTIHYPERTENSIVES AND MAOI'S HAVE A ADDITIVE WHAT EFFECT | HYPOTENSIVE |
MEPERIDINE/DEMEROL AND MAOI'SCAN LEAD TO WHAT | HYPERPYREXIA |
CONCURRENT USE OF VASOPRESSORS AND MAOI'S RESULT IN WHAT | HYPERTENSION |
WHAT ARE MEDICATIONS THAT ARE LISTED AS ATYPICAL ANTIDEPRESSANTS | BUPROPRION HCL/WELLBUTRIN |
WHAT IS THE EXPECTED PHARMACOLOGICAL ACTION OF ATYPICAL ANTI-DEPRESSANTS | INHIBITING DOPAMINE UPTAKE |
THERAPEUTIC USES OF ATYPICAL ANTI-DEPRESSANTS ARE | TREATMENT OF DEPRESSION
ALTERNATIVE TO SSRI'S FOR CLIENTS UNABLE TO TOLERATE SEXUAL DYSFUNCTION SIDE EFFECTS OF SSRI'S
AID TO QUIT SMOKING
PREVENTION OF SAD |
SIDE EFFECTS OF ATYPICAL ANTI-DEPRESSANTS | HEADACHE
DRY MOUTH
GI DISTRESS
CONSTIPATION
INCREASED HEART RATE
NAUSEA
RESTLESSNESS
INSOMNIA
SUPRESSION OF APPETITE
WEIGHT LOSS
SEIZURES |
BUPROPRION HCL/WELLBUTRIN IS A PREGNANCY RISK CATEGORY WHAT | B |
ATYPICAL ANTI-DEPRESSANTS ARE CONTRAINDICATED IN CLIENTS THAT ARE | TAKING MAOI'S |
ATYPICAL ANTI-DEPRESSANTS ARE USED CAUTIOUSLY IN CLIENTS WHO HAVE | SEIZURE DISORDERS |
ATYPICAL ANTI-DEPRESSANTS INTERACT WITH MAOI'S AND INCREASE THE RISK OF | TOXICITY |
OTHER ATYPICAL ANTIDEPRESSANTS ARE | VENLAFAXINE/EFFEXOR
DULOXETINE/CYMBALTA (SNRI'S)
MIRTAZAPINE/REMERON
REBOXETINE/EDRONAX
TRAZADONE/DESYREL |
EFFEXOR AND CYMBALTA'S PHARMACOLOGICAL ACTION IS | INHIBIT SEROTONIN AND NOREPINEPHRINE REUPTAKE THEREBY INCREASING THE AMOUNT OF THESE NEUROTRANSMITTERS AVAILABLE IN BRAIN IMPULSE TRANSMISSION |
MIRTAZAPINE/REMERON'S PHARMACOLOGICAL ACTION | INCREASE RELEASE OF SEROTONIN AND NOREPINEPHRINE AND THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION |
REBOXETINE/EDRONAX'S PHARMACOLOGICAL ACTION | SELECTIVELY INHIBITS THE REUPTAKE OF NOREPINEPHRINE THEREBY INCREASING THE AMOUNT OF NEUROTRANSMITTERS AVAILABLE FOR IMPULSE TRANSMISSION |
TRAZADONE/DESYREL'S PHARMACOLOGICAL ACTION | HAS MODERATE SELECTIVE BLOCKADE OF SEROTONIN RECEPTORS WHICH ALLOWS MORE SEROTONIN TO BE AVAILABLE FOR IMPULSE TRANSMISSION |